Monitor the German sales recovery and the timing of the DrugSorb-ATR De Novo submission to FDA in early 2027. Cash runway remains tight at $5.7M, so any delay in revenue growth or regulatory milestones could increase financing risk.
Drugs in focus
CTSO drug pipeline →CytoSorb
▼ Bearish Named in this press release- Impact
- Phase
- Approved / Commercialized
- Time to market
- Already on the market (CE-marked in Europe, FDA-cleared in US)
- Next catalyst
- None dated
What to watchWatch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 13 $4.87entry
- T+1 · 6d ago −0.41%α +1.50% · $4.85
- T+5 · 2d ago −14.58%α −6.02% · $4.16
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CytoSorbents reported Q3 2026 revenue of $9.7M (+3% YoY), slightly below the $9.9M consensus, and a GAAP net loss of $0.58 per share, which was narrower than the $-0.90 consensus estimate. The company achieved operating cash flow breakeven (excluding restructuring payments), a key milestone, but revenue growth remains modest and the German market declined 20% YoY.
Key Financial Metrics
Key Facts
- Revenue $9.7M, +3% YoY vs $9.5M (consensus $9.9M)
- GAAP net loss $0.58 per share vs consensus $-0.90 (narrower loss)
- Operating cash flow positive $43K (excluding $251K restructuring payments), achieving breakeven target
- Gross margin improved to 75% from 70% a year ago
- Germany sales declined 20% YoY, representing 24% of quarterly sales
- Cash and restricted cash $5.7M at quarter end
- Adjusted EBITDA loss narrowed 86% to $0.3M
Financial Impact
Revenue $9.7M, net loss $1.8M, operating cash flow $43K positive (ex-restructuring)
Risk Factors
- Revenue growth of only 3% YoY, below consensus estimate
- Germany sales declined 20% YoY, a key market
- Cash position $5.7M may require additional financing before breakeven is sustained
- Regulatory approval for DrugSorb-ATR is uncertain and subject to FDA review
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302938462 |
Track record
12 reports on CTSO
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20261d ago 424B5 Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 20, 20261d ago 8-K Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 19, 20263d ago 8-K/A Neutral 4/10 Entry $5.13 Now $4.16 −18.91% settles Feb 18
- Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
- Nov 12, 20269d ago Press Release Neutral 4/10 Viewing Entry $4.87 Now $4.16 −14.58% settles Feb 11
- Nov 12, 20269d ago 8-K Neutral 5/10 No price data
- Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
- Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
- Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
- Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers